59 related articles for article (PubMed ID: 37275740)
1. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia.
Killander D; Dohlwitz A; Engstedt L; Franzén S; Gahrton G; Gullbring B; Holm G; Holmgren A; Höglund S; Killander A; Lockner D; Mellstedt H; Moe PJ; Palmblad J; Reizenstein P; Skårberg KO; Swedberg B; Udén AM; Wadman B; Wide L; Ahström L
Cancer; 1976 Jan; 37(1):220-8. PubMed ID: 1061636
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of acute lymphoblastic leukemia with pegasparaginase.
Masetti R; Pession A
Biologics; 2009; 3():359-68. PubMed ID: 19707421
[TBL] [Abstract][Full Text] [Related]
3. Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
Taurino G; Dander E; Chiu M; Pozzi G; Maccari C; Starace R; Silvestri D; Griffini E; Bianchi MG; Carubbi C; Andreoli R; Mirandola P; Valsecchi MG; Rizzari C; D'Amico G; Bussolati O
Br J Haematol; 2024 May; ():. PubMed ID: 38736325
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.
Brigitha LJ; Mondelaers V; Liu Y; Albertsen BK; Zalewska-Szewczyk B; Rizzari C; Kotecha RS; Pieters R; Huitema ADR; van der Sluis IM
Pharm Res; 2024 Apr; 41(4):711-720. PubMed ID: 38538970
[TBL] [Abstract][Full Text] [Related]
5. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity Reactions to Native
Möricke A; Rizzari C; Alten J; Attarbaschi A; Beier R; Biondi A; Burkhardt B; Bodmer N; Boos J; Cario G; Conter V; Flotho C; Kulozik A; Lanvers-Kaminsky C; Mann G; Niggli F; Silvestri D; von Stackelberg A; Stanulla M; Valsecchi MG; Schrappe M; Zimmermann M
Hemasphere; 2023 Jun; 7(6):e888. PubMed ID: 37275738
[No Abstract] [Full Text] [Related]
7. Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Maese L; Rau RE
Front Pediatr; 2022; 10():902117. PubMed ID: 35844739
[TBL] [Abstract][Full Text] [Related]
8. Asparaginase: an old drug with new questions.
Cecconello DK; Magalhães MR; Werlang ICR; Lee MLM; Michalowski MB; Daudt LE
Hematol Transfus Cell Ther; 2020; 42(3):275-282. PubMed ID: 31801703
[TBL] [Abstract][Full Text] [Related]
9. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol.
Rizzari C; Möricke A; Valsecchi MG; Conter V; Zimmermann M; Silvestri D; Attarbaschi A; Niggli F; Barbaric D; Stary J; Elitzur S; Cario G; Vinti L; Boos J; Zucchetti M; Lanvers-Kaminsky C; von Stackelberg A; Biondi A; Schrappe M
Hemasphere; 2023 Jun; 7(6):e893. PubMed ID: 37275740
[TBL] [Abstract][Full Text] [Related]
11. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V; Valsecchi MG; Cario G; Zimmermann M; Attarbaschi A; Stary J; Niggli F; Dalla Pozza L; Elitzur S; Silvestri D; Locatelli F; Möricke A; Engstler G; Smisek P; Bodmer N; Barbaric D; Izraeli S; Rizzari C; Boos J; Buldini B; Zucchetti M; von Stackelberg A; Matteo C; Lehrnbecher T; Lanvers-Kaminsky C; Cazzaniga G; Gruhn B; Biondi A; Schrappe M
J Clin Oncol; 2024 Mar; 42(8):915-926. PubMed ID: 38096462
[TBL] [Abstract][Full Text] [Related]
12. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
14. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
